Drug Neurology

Dysport

Payments companies reported to CMS as associated with Dysport. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.7Massociated payments (2023-2025)

9,129clinicians with associated payments

5companies reporting

By year

2023 $1.1M

2024 $1.2M

2025 $1.4M

Payments reported as associated with Dysport, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Physical Medicine & Rehabilitation $1.8M

Neurology (Psychiatry & Neurology) $861K

Brain Injury Medicine (Physical Medicine & Rehabilitation) $309K

Dermatology $113K

Pediatric Rehabilitation Medicine $107K

Physician Assistant $71K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Dysport

These are the largest totals companies reported as associated with Dysport. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Monica Verduzco-Gutierrez	San Antonio, TX	Brain Injury Medicine (Physical Medicine & Rehabilitation)	$306,567.96
Michael Saulino	Elkins Park, PA	Physical Medicine & Rehabilitation	$244,894.93
Jose Urquidez	Austin, TX	Physical Medicine & Rehabilitation	$244,232.28
Atul Patel	Overland Park, KS	Physical Medicine & Rehabilitation	$208,295.26
Shivani Gupta	Oak Lawn, IL	Physical Medicine & Rehabilitation	$187,004.48
Laxman Bahroo	Washington, DC	Neurology (Psychiatry & Neurology)	$186,740.64
Nicholas Ketchum	Milwaukee, WI	Physical Medicine & Rehabilitation	$148,848.70
Aaron Ellenbogen	Farmington Hills, MI	Neurology (Psychiatry & Neurology)	$112,045.40
Karin Goodfriend	Milwaukee, WI	Physical Medicine & Rehabilitation	$109,975.52
Joshua Vova	Atlanta, GA	Pediatric Rehabilitation Medicine	$84,179.26

Prescribed Dysport?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.